Article: Targeted Genetics Reports Second Quarter 1997 Financials

SEATTLE, July 31 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN) today reported a net loss of $3.8 million, or $0.19 per share, for the quarter ended June 30, 1997. For the comparable period in 1996, the company's net loss was $16.4 million, or $1.26 per share, which included a one-time, non-cash charge of $13.5 million related to the June 1996 acquisition of RGene Therapeutics, Inc. Excluding this charge, the comparable net loss would have been $2.9 million, or $0.22 per share.

The increased net loss, after adjustment for the prior year charge, primarily resulted from a planned increase in research and development spending. A majority of the ...






Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!